Mild cognitive impairment due to Alzheimer disease in the community

The newly proposed National Institute on Aging–Alzheimer's Association (NIA‐AA) criteria for mild cognitive impairment (MCI) due to Alzheimer disease (AD) suggest a combination of clinical features and biomarker measures, but their performance in the community is not known.

[1]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[2]  B. Yawn,et al.  History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. , 2012, Mayo Clinic proceedings.

[3]  C. Jack,et al.  An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease , 2012, Annals of neurology.

[4]  J. Gunter,et al.  Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease , 2012, Neurology.

[5]  W. Jagust,et al.  Association of lifetime cognitive engagement and low β-amyloid deposition. , 2012, Archives of neurology.

[6]  B. Yawn,et al.  Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project. , 2012, Mayo Clinic proceedings.

[7]  C. Jack,et al.  Evidence for ordering of Alzheimer disease biomarkers. , 2011, Archives of neurology.

[8]  L. McEvoy,et al.  Predicting MCI outcome with clinically available MRI and CSF biomarkers , 2011, Neurology.

[9]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[10]  C. Rowe,et al.  Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study , 2011, Neuropsychologia.

[11]  R. Petersen.  Clinical practice. Mild cognitive impairment. , 2011, The New England journal of medicine.

[12]  B. Yawn,et al.  American Journal of Epidemiology Practice of Epidemiology Use of a Medical Records Linkage System to Enumerate a Dynamic Population over Time: the Rochester Epidemiology Project , 2022 .

[13]  C. Jack,et al.  Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease , 2010, Brain : a journal of neurology.

[14]  M. Weiner,et al.  Automated MRI measures predict progression to Alzheimer's disease , 2010, Neurobiology of Aging.

[15]  Cindee M. Madison,et al.  Comparing predictors of conversion and decline in mild cognitive impairment , 2010, Neurology.

[16]  Norbert Schuff,et al.  Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease , 2010, NeuroImage.

[17]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[18]  C. Jack,et al.  Mild cognitive impairment: ten years later. , 2009, Archives of neurology.

[19]  M. Weiner,et al.  Relationships between biomarkers in aging and dementia , 2009, Neurology.

[20]  D. Knopman,et al.  Amyloid imaging in the prediction of Alzheimer-type dementia in subjects with amnestic MCI , 2009, Neurology.

[21]  C. Jack,et al.  MRI and CSF biomarkers in normal, MCI, and AD subjects , 2009, Neurology.

[22]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[23]  C. Jack,et al.  Comparison of 18F-FDG and PiB PET in Cognitive Impairment , 2009, Journal of Nuclear Medicine.

[24]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[25]  C. Jack,et al.  MRI correlates of neurofibrillary tangle pathology at autopsy , 2008, Neurology.

[26]  Clifford R. Jack,et al.  Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage , 2008, NeuroImage.

[27]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[28]  C. Jack,et al.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.

[29]  V. Pankratz,et al.  The Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and Sample Characteristics , 2008, Neuroepidemiology.

[30]  R. Mayeux,et al.  Hippocampal and entorhinal atrophy in mild cognitive impairment , 2007, Neurology.

[31]  E. Tangalos,et al.  Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. , 2006, Archives of neurology.

[32]  S. DeKosky,et al.  Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  R. Petersen.  Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[34]  Armando Manduca,et al.  Methodological considerations for measuring rates of brain atrophy , 2003, Journal of magnetic resonance imaging : JMRI.

[35]  W. Klunk,et al.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. , 2003, Journal of medicinal chemistry.

[36]  E. Kaplan,et al.  The Boston naming test , 2001 .

[37]  A M Dale,et al.  Measuring the thickness of the human cerebral cortex from magnetic resonance images. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[38]  C. Jack,et al.  MRI‐Based Hippocampal Volume Measurements in Epilepsy , 1994, Epilepsia.

[39]  P. Rubé,et al.  L’examen Clinique en Psychologie , 1959 .

[40]  R. Reitan.  Validity of the Trail Making Test as an Indicator of Organic Brain Damage , 1958 .

[41]  Nick C. Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association workgroup , 2011 .

[42]  Charles D. Smith,et al.  Neuropathologic substrate of mild cognitive impairment. , 2006, Archives of neurology.

[43]  J. J. Ryan,et al.  Wechsler Adult Intelligence Scale-III , 2001 .

[44]  E. Tangalos,et al.  Neuropsychological tests' norms above age 55: COWAT, BNT, MAE token, WRAT-R reading, AMNART, STROOP, TMT, and JLO , 1996 .

[45]  E. Tangalos,et al.  Mayo's older americans normative studies: WAIS-R norms for ages 56 to 97 , 1992 .

[46]  James F. Malec,et al.  Mayo's older americans normative studies: Updated AVLT norms for ages 56 to 97 , 1992 .

[47]  Robert A. Bornstein,et al.  The Wechsler Memory Scale—Revised , 1990 .